Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 25;6(3):56.
doi: 10.3390/vaccines6030056.

Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy

Sandra Tuyaerts  1   2 , Frédéric Amant  3   4   5   6
Affiliations
Review

Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy

Sandra Tuyaerts et al. Vaccines (Basel). .

Abstract

Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising targets for immunotherapeutic approaches. In this review, we first describe the current knowledge about the classification of endometrial stromal sarcomas, and their molecular and genetic characteristics. Next, we summarize the available data on the use of translocation breakpoints as immunotherapeutic targets. Finally, we propose a roadmap to evaluate the feasibility of immunologic targeting of the endometrial stromal sarcoma-specific translocations in patients with recurrent disease.

Keywords: endometrial stromal sarcoma; immunotherapy; neoantigen; recurrent chromosomal translocations.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of immunogenicity testing of the translocation breakpoints in ESS.
Figure 2
Figure 2
Proposed decision tree for treatment allocation to ESS patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Amant F., Floquet A., Friedlander M., Kristensen G., Mahner S., Nam E.J., Powell M.A., Ray-Coquard I., Siddiqui N., Sykes P., et al. Gynecologic cancer intergroup (GCIG) consensus review for endometrial stromal sarcoma. Int. J. Gynecol. Cancer. 2014;24:S67–S72. doi: 10.1097/IGC.0000000000000205. - DOI - PubMed
    1. Gantzer J., Ray-Coquard I. Gynecological sarcomas: What‘s new in 2018, a brief review of published literature. Curr. Opin. Oncol. 2018;30:246–251. doi: 10.1097/CCO.0000000000000462. - DOI - PubMed
    1. Anguille S., Van de Velde A.L., Smits E.L., Van Tendeloo V.F., Juliusson G., Cools N., Nijs G., Stein B., Lion E., Van Driessche A., et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130:1713–1721. doi: 10.1182/blood-2017-04-780155. - DOI - PMC - PubMed
    1. Rosenblatt J., Stone R.M., Uhl L., Neuberg D., Joyce R., Levine J.D., Arnason J., McMasters M., Luptakova K., Jain S., et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci. Transl. Med. 2016;8 doi: 10.1126/scitranslmed.aag1298. - DOI - PMC - PubMed
    1. Hayashi M., Chu D., Meyer C.F., Llosa N.J., McCarty G., Morris C.D., Levin A.S., Wolinsky J.P., Albert C.M., Steppan D.A., et al. Highly personalized detection of minimal ewing sarcoma disease burden from plasma tumor DNA. Cancer. 2016;122:3015–3023. doi: 10.1002/cncr.30144. - DOI - PMC - PubMed

LinkOut - more resources